These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

583 related items for PubMed ID: 28403877

  • 21. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
    Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S.
    Cardiovasc Diabetol; 2020 Jun 15; 19(1):89. PubMed ID: 32539832
    [Abstract] [Full Text] [Related]

  • 22. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Li D, Shi W, Wang T, Tang H.
    Diabetes Obes Metab; 2018 Aug 15; 20(8):1972-1976. PubMed ID: 29573110
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
    Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Gouda M, Iijima H, Watanabe Y.
    Diabetes Obes Metab; 2018 Feb 15; 20(2):453-457. PubMed ID: 28786530
    [Abstract] [Full Text] [Related]

  • 24. Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE).
    de Boer SA, Heerspink HJL, Juárez Orozco LE, van Roon AM, Kamphuisen PW, Smit AJ, Slart RHJA, Lefrandt JD, Mulder DJ.
    Diabetes Obes Metab; 2017 Aug 15; 19(8):1147-1154. PubMed ID: 28244635
    [Abstract] [Full Text] [Related]

  • 25. The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
    van Hulten V, Driessen JHM, Starup-Linde JK, Al-Mashhadi ZK, Viggers R, Klungel OH, Souverein PC, Vestergaard P, Stehouwer CDA, van den Bergh JP.
    Diabetes Obes Metab; 2023 Nov 15; 25(11):3235-3247. PubMed ID: 37503747
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
    Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K.
    Diabetes Obes Metab; 2018 May 15; 20(5):1176-1185. PubMed ID: 29316236
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program.
    Gadzhanova S, Pratt N, Roughead E.
    Diabetes Res Clin Pract; 2017 Aug 15; 130():180-185. PubMed ID: 28646701
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
    Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, Bramlage P, Schiffer M, Schmieder RE.
    Cardiovasc Diabetol; 2021 Sep 04; 20(1):178. PubMed ID: 34481498
    [Abstract] [Full Text] [Related]

  • 33. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
    Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Zannad F, Liu Y, Gourlie NM, Cannon CP, EXAMINE Investigators.
    Diabetes Obes Metab; 2017 May 04; 19(5):664-671. PubMed ID: 28058763
    [Abstract] [Full Text] [Related]

  • 34. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
    Ridderstråle M, Svaerd R, Zeller C, Kim G, Woerle HJ, Broedl UC, EMPA-REG H2H-SU trial investigators.
    Cardiovasc Diabetol; 2013 Sep 05; 12():129. PubMed ID: 24007456
    [Abstract] [Full Text] [Related]

  • 35. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Guthrie RM.
    Postgrad Med; 2015 Jun 05; 127(5):463-79. PubMed ID: 25956345
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR, TECOS Executive Committee.
    Diabetes Obes Metab; 2015 Apr 05; 17(4):395-402. PubMed ID: 25600421
    [Abstract] [Full Text] [Related]

  • 39. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N.
    Cardiovasc Diabetol; 2017 Jan 21; 16(1):13. PubMed ID: 28109295
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.